Sort by
Keyphrases
Randomized Trial
100%
Meta-analysis
100%
Systematic Meta-analysis
100%
Adjuvant Chemotherapy
100%
Muscle-invasive Bladder Cancer
100%
Invasive Bladder Cancer
100%
Disease-free Survival
75%
Cisplatin-based Chemotherapy
75%
Confidence Interval
50%
Hazard Ratio
50%
Overall Survival
50%
Randomized Controlled Trial
50%
Survival Benefit
50%
Surgery Alone
25%
American Society of Clinical Oncology
25%
Cochrane Central Register of Controlled Trials
25%
Embase
25%
MEDLINE
25%
Patients Included
25%
Comprehensive Literature Review
25%
Nodal Involvement
25%
Radical Cystectomy
25%
Evidence Acquisition
25%
Limited Power
25%
Trial Reporting
25%
Nursing and Health Professions
Systematic Review
100%
Meta Analysis
100%
Adjuvant Chemotherapy
100%
Muscle Invasive Bladder Cancer
100%
Bladder Cancer
100%
Disease Free Survival
75%
Cisplatin
75%
Confidence Interval
50%
Overall Survival
50%
Hazard Ratio
50%
Medline
25%
Cochrane Library
25%
Embase
25%
Literature Review
25%
Cystectomy
25%
Medicine and Dentistry
Meta-Analysis
100%
Systematic Review
100%
Adjuvant Chemotherapy
100%
Muscle Invasive Bladder Cancer
100%
Invasive Bladder Cancer
100%
Cisplatin
75%
Disease Free Survival
75%
Hazard Ratio
50%
Overall Survival
50%
Randomized Controlled Trial
50%
Clinical Oncology
25%
Cystectomy
25%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Bladder Cancer
100%
Muscle Invasive Bladder Cancer
66%
Disease Free Survival
50%
Cisplatin
50%
Overall Survival
33%
Randomized Controlled Trial
33%